Related Experiment Video
Updated: Jan 19, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Managing Lung Cancer with Comorbid Interstitial Pneumonia
Eiki Ichihara1, Nobuaki Miyahara2, Yoshinobu Maeda3
1Department of Allergy and Respiratory Medicine, Okayama University Hospital, Japan.
Systemic therapies for advanced non-small cell lung cancer (NSCLC) show promise, but patients with interstitial pneumonia (IP) are often excluded. This review addresses pharmacotherapy challenges in advanced NSCLC with comorbid IP.
Area of Science:
- Oncology
- Pulmonology
- Pharmacology
Background:
- Systemic therapy for advanced non-small cell lung cancer (NSCLC) has advanced significantly with molecular-targeted therapy and immune checkpoint inhibitors.
- Patients with comorbid interstitial pneumonia (IP), particularly idiopathic pulmonary fibrosis (IPF), are frequently excluded from clinical trials.
- Acute exacerbations of IP can occur during cancer treatments, posing risks for patients with lung cancer and IP.
Purpose of the Study:
- To review the clinical challenges of pharmacotherapy for advanced NSCLC in patients with comorbid IP.
- To discuss current data and potential strategies for managing these complex cases.
Main Methods:
- Literature review focusing on clinical trials and studies involving advanced NSCLC and comorbid IP.
- Analysis of pharmacotherapy options and their impact on IP exacerbation.
- Discussion of existing data and clinical recommendations.
Main Results:
- Most clinical trials for advanced NSCLC treatments exclude patients with comorbid IP.
- IP, especially IPF, is common in lung cancer patients and can be exacerbated by cancer therapies.
- Limited data exists on the safety and efficacy of systemic therapies in this specific patient population.
Conclusions:
- There is a critical unmet need for evidence-based guidelines for treating advanced NSCLC with comorbid IP.
- Further research is required to understand the risks and benefits of various pharmacotherapies in this population.
- A multidisciplinary approach is essential for managing these complex patients.
Related Concept Videos
COPD: Management Using Bronchodilators and Corticosteroids
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Chronic Obstructive Pulmonary Disease-V: Nursing Management
Assessment
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:

